Why we need proper PBPK models to examine intestine and liver oral drug absorption

Current Drug Metabolism

Volumn 14, Issue 1, 2013, Pages 57-79

  Chow, Edwin C Y ^a   Pang, K Sandy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Intestinal flow, enterocyte flow; Intestine models; Transporters

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ATORVASTATIN; BERBERINE; CARRIER PROTEIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DIGOXIN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; DRUG RECEPTOR; EVEROLIMUS; FLAVONOID; GEPIRONE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; ITRACONAZOLE; KETOCONAZOLE; LITHOCHOLIC ACID; MIDAZOLAM; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; RIFAMPICIN; SAQUINAVIR; SULFOTRANSFERASE; TALINOLOL; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; COLON; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EXCRETION; DRUG METABOLISM; DUODENUM; ENZYME INDUCTION; ENZYME INHIBITION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GASTROINTESTINAL MOTILITY; GRAPEFRUIT JUICE; GROUPS BY AGE; HUMAN; ILEUM; INTESTINE EPITHELIUM CELL; JEJUNUM; LIVER METABOLISM; MATHEMATICAL MODEL; MODEL; NONHUMAN; PHYSIOLOGICAL BASED PHARMACOKINETIC MODEL; PREDICTION; STOMACH EMPTYING; THEORETICAL MODEL;

EID: 84871294584     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804545124     Document Type: Article

References (262)

1. Pang, K. S.; Morris, M. E.; Sun, H. Formed and preformed metabolites: facts and comparisons. J. Pharm. Pharmacol., 2008, 60(10), 1247-1275.
2. Chen, J.; Pang, K. S. Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. J. Pharmacol. Exp. Ther., 1997, 280(1), 24-31.
3. Xu, X.; Hirayama, H.; Pang, K. S. First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation. Drug Metab. Dispos., 1989, 17(5), 556-563.
4. Pang, K. S. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos., 2003, 31(12), 1507-1519.
5. Iwamoto, K.; Takei, M.; Watanabe, J. Gastrointestinal and hepatic first-pass metabolism of aspirin in rats. J. Pharm. Pharmacol, 1982, 34(3), 176-180.
6. Kim, J.; Kim, S. H.; Lee, M. G. Liver and gastrointestinal first-pass effects of azosemide in rats. J. Pharm. Pharmacol., 1997, 49(9), 878-883.
7. Liu, Y. T.; Hao, H. P.; Xie, H. G.; Lai, L.; Wang, Q.; Liu, C. X.; Wang, G. J. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab. Dispos., 2010, 38(10), 1779-1784.
8. Plänitz, V.; Grönniger, J.; Jähnchen, E. Prehepatic and hepatic firstpass metabolism of lorcainide in rats. Arzneimittelforschung, 1985, 35(6), 923-926.
9. Paine, M. F.; Shen, D. D.; Kunze, K. L.; Perkins, J. D.; Marsh, C. L.; McVicar, J. P.; Barr, D. M.; Gillies, B. S; Thummel, K. E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 1996, 60(1), 14-24.
10. van Herwaarden, A. E.; Wagenaar, E.; van der Kruijssen, C. M.; van Waterschoot, R. A.; Smit, J. W.; Song, J. Y.; van der Valk, M. A.; van Tellingen, O.; van der Hoorn, J. W.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest., 2007, 117(11), 3583-3592.
11. Zhang, Q. Y.; Kaminsky, L. S.; Dunbar, D.; Zhang, J.; Ding, X. Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine. Drug Metab. Dispos., 2007, 35(9), 1617-1623.
12. Fang, C.; Zhang, Q. Y. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo [a]pyrene. J. Pharmacol. Exp. Ther., 2010, 334(1), 156-163.
13. Zhang, Q. Y.; Fang, C.; Zhang, J.; Dunbar, D.; Kaminsky, L.; Ding, X. An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal P450s in first-pass clearance of oral nifedipine. Drug Metab. Dispos., 2009, 37(3), 651-657.
14. Zhu, Y.; D'Agostino, J.; Zhang, Q. Y. Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab. Dispos., 2011, 39(6), 939-943.
15. Fromm, M. F.; Busse, D.; Kroemer, H. K.; Eichelbaum, M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 1996, 24(4), 796-801.
16. Thummel, K. E.; O'Shea, D.; Paine, M. F.; Shen, D. D.; Kunze, K. L.; Perkins, J. D.; Wilkinson, G. R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 1996, 59(5), 491-502.
17. Iwamoto, K.; Klaassen, C. D. First-pass effect of morphine in rats. J. Pharmacol. Exp. Ther., 1977, 200(1), 236-244.
18. Zhang, L.; Lin, G.; Chang, Q.; Zuo, Z. Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm. Res., 2005, 22(7), 1050-1058.
19. Lledó-García, R.; Nácher, A.; Casabó, V. G.; Merino-Sanjuán, M. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug Metab. Dispos., 2011, 39(2), 294-301.
20. Kaminsky, L. S.; Zhang, Q. Y. The small intestine as a xenobioticmetabolizing organ. Drug Metab. Dispos., 2003, 31(12), 1520-1525.
21. Hickman, D.; Pope, J.; Patil, S. D.; Fakis, G.; Smelt, V.; Stanley, L. A.; Payton, M.; Unadkat, J. D.; Sim, E. Expression of arylamine N-acetyltransferase in human intestine. Gut, 1998, 42(3), 402-409.
22. Coles, B. F.; Chen, G.; Kadlubar, F. F.; Radominska-Pandya, A. Interindividual variation and organ-specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. Arch. Biochem. Biophys., 2002, 403(2), 270-276.
23. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34(5), 880-886.
24. Tukey, R. H.; Strassburg, C. P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol. Pharmacol., 2001, 59(3), 405-414.
25. Tam, D.; Tirona, R. G.; Pang, K. S. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab. Dispos., 2003, 31(4), 373-383.
26. Cao, X.; Gibbs, S. T.; Fang, L.; Miller, H. A.; Landowski, C. P.; Shin, H. C.; Lennernas, H.; Zhong, Y.; Amidon, G. L.; Yu, L. X.; Sun, D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 2006, 23(8), 1675-1686.
27. Imai, T.; Imoto, M.; Sakamoto, H.; Hashimoto, M. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab. Dispos., 2005, 33(8), 1185-1190.
28. Anzenbacher, P.; Anzenbacherová, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life. Sci., 2001, 58(5-6), 737-747.
29. de Waziers, I.; Cugnenc, P. H.; Yang, C. S.; Leroux, J. P.; Beaune, P. H. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther., 1990, 253(1), 387-394.
30. Ilett, K. F.; Tee, L. B.; Reeves, P. T.; Minchin, R. F. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol. Ther, 1990, 46(1), 67-93.
31. Shin, H. C.; Kim, H. R.; Cho, H. J.; Yi, H.; Cho, S. M.; Lee, D. G.; Abd El-Aty, A. M.; Kim, J. S.; Sun, D.; Amidon, G. L. Comparative gene expression of intestinal metabolizing enzymes. Biopharm. Drug. Dispos., 2009, 30(8), 411-421.
32. Galetin, A.; Gertz, M.; Houston, J. B. Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab. Pharmacokinet., 2010, 25(1), 28-47.
33. Paine, M. F.; Khalighi, M.; Fisher, J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 1997, 283(3), 1552-1562.
34. Zhang, Q. Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L. S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 1999, 27(7), 804-809.
35. Her, C.; Szumlanski, C.; Aksoy, I. A.; Weinshilboum, R. M. Human jejunal estrogen sulfotransferase and dehydroepiandrosterone sulfotransferase: immunochemical characterization of individual variation. Drug Metab. Dispos., 1996, 24(12), 1328-1335.
36. Strassburg, C. P.; Nguyen, N.; Manns, M. P.; Tukey, R. H. UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology, 1999, 116(1), 149-160.
37. Radominska-Pandya, A.; Little, J. M.; Pandya, J. T.; Tephly, T. R.; King, C. D.; Barone, G. W.; Raufman, J. P. UDP-glucuronosyltransferases in human intestinal mucosa. Biochim. Biophys. Acta., 1998, 1394(2-3), 199-208.
38. Nakamura, A.; Nakajima, M.; Yamanaka, H.; Fujiwara, R.; Yokoi, T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos., 2008, 36(8), 1461-1464.
39. Ohno, S.; Nakajin, S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptasepolymerase chain reaction. Drug Metab. Dispos., 2009, 37(1), 32-40.
40. Strassburg, C. P.; Kneip, S.; Topp, J.; Obermayer-Straub, P.; Barut, A.; Tukey, R. H.; Manns, M. P. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem, 2000, 275(46), 36164-36171.
41. Bernard, O.; Guillemette, C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos., 2004, 32(8), 775-778.
42. Basu, N. K.; Ciotti, M.; Hwang, M. S.; Kole, L.; Mitra, P. S.; Cho, J. W.; Owens, I. S. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem., 2004, 279(2), 1429-1441.
43. Picard, N.; Ratanasavanh, D.; Prémaud, A.; Le Meur, Y.; Marquet, P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos., 2005, 33(1), 139-146.
44. Mizuma, T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int. J. Pharm., 2009, 378(1-2), 140-141.
45. Kosaka, K.; Sakai, N.; Endo, Y.; Fukuhara, Y.; Tsuda-Tsukimoto, M.; Ohtsuka, T.; Kino, I.; Tanimoto, T.; Takeba, N.; Takahashi, M.; Kume, T. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab. Dispos., 2011, 39(9), 1495-1502.
46. Bullingham, R. E.; Nicholls, A. J.; Kamm, B. R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet., 1998, 34(6), 429-455.
47. Shipkova, M.; Armstrong, V. W.; Wieland, E.; Niedmann, P. D.; Schütz, E.; Brenner-Weiss, G.; Voihsel, M.; Braun, F.; Oellerich, M. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol., 1999, 126(5), 1075-1082.
48. Inoue, H.; Yuki, G.; Yokota, H.; Kato, S. Bisphenol A glucuronidation and absorption in rat intestine. Drug Metab. Dispos., 2003, 31(1), 140-144.
49. Fisher, J. W.; Twaddle, N. C.; Vanlandingham, M.; Doerge, D. R. Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicol. Appl. Pharmacol., 2011, 257(1), 122-136.
50. Riches, Z.; Stanley, E. L.; Bloomer, J. C.; Coughtrie, M. W. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab. Dispos., 2009, 37(11), 2255-2261.
51. Klaassen, C. D.; Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev., 2010, 62(1), 1-96.
52. Halestrap, A. P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers. Arch., 2004, 447(5), 619-628.
53. You, G.; Morris, M. E. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Wiley-Interscience, Hoboken, N. J., 2007.
54. Dietrich, C. G.; Geier, A.; Oude Elferink, R. P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut., 2003, 52(12), 1788-1795.
55. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H. P.; von Richter, O.; Zundler, J.; Kroemer, H. K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 1999, 104(2), 147-153.
56. Westphal, K.; Weinbrenner, A.; Zschiesche, M.; Franke, G.; Knoke, M.; Oertel, R.; Fritz, P.; von Richter, O.; Warzok, R.; Hachenberg, T.; Kauffmann, H. M.; Schrenk, D.; Terhaag, B.; Kroemer, H. K.; Siegmund, W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther., 2000, 68(4), 345-355.
57. Haslam, I. S.; Wright, J. A.; O'Reilly, D. A.; Sherlock, D. J.; Coleman, T.; Simmons, N. L. Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2). Drug Metab. Dispos., 2011, 39(12), 2321-2328.
58. Jonker, J. W.; Smit, J. W.; Brinkhuis, R. F.; Maliepaard, M.; Beijnen, J. H.; Schellens, J. H.; Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92(20), 1651-1656.
59. Dahan, A.; Amidon, G. L. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int. J. Pharm., 2010, 386(1-2), 216-220.
60. Vlaming, M. L.; Pala, Z.; van Esch, A.; Wagenaar, E.; de Waart, D. R.; van de Wetering, K.; van der Kruijssen, C. M.; Oude Elferink, R. P.; van Tellingen, O.; Schinkel, A. H. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res., 2009, 15(9), 3084-3093.
61. Juan, M. E.; González-Pons, E.; Planas, J. M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr., 2010, 140(3), 489-495.
62. Dahan, A.; Amidon, G. L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol, 2009. 297(2), G371-G377.
63. Lin, J. H.; Chiba, M.; Baillie, T. A. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 1999, 51(2), 135-158.
64. Mouly, S.; Lown, K. S.; Kornhauser, D.; Joseph, J. L.; Fiske, W. D.; Benedek, I. H.; Watkins, P. B. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther., 2002, 72(1), 1-9.
65. Liu, X. G.; Narang, P. K.; Li, R. C. Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. Eur. J. Drug Metab. Pharmacokinet., 2001, 26(4), 209-213.
66. Catania, V. A.; Sánchez Pozzi, E. J.; Luquita, M. G.; Ruiz, M. L.; Villanueva, S. S.; Jones, B.; Mottino, A. D. Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2. Ann. Hepatol., 2004, 3(1), 11-17.
67. Urquhart, B. L.; Tirona, R. G.; Kim, R. B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47(5), 566-578.
68. Tirona, R. G. Molecular mechanisms of drug transporter regulation. Handb. Exp. Pharmacol., 2011, 201, 373-402.
69. Kolars, J. C.; Schmiedlin-Ren, P.; Schuetz, J. D.; Fang, C.; Watkins, P. B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest., 1992, 90(5), 1871-1878.
70. Watkins, P. B.; Wrighton, S. A.; Schuetz, E. G.; Molowa, D. T.; Guzelian, P. S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest, 1987, 80(4), 1029-1036.
71. Chow, E. C.; Durk, M. R.; Cummins, C. L.; Pang, K. S. 1a, 25-Dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr (-/-) and fxr (+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J. Pharmacol. Exp. Ther., 2011, 337(3), 846-859.
72. Xiao, L.; Xie, X.; Zhai, Y. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. Adv. Drug Deliv. Rev., 2010, 62(13), 1316-1321.
73. Zordoky, B. N.; El-Kadi, A. O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab., 2009, 10(2), 164-178.
74. Runge-Morris, M.; Kocarek, T. A. Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. PPAR Res., 2009, 2009, 728941.
75. 3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm. Drug. Dispos., 2010, 31(1), 91-108.
76. Zhou, S. F.; Wang, B.; Yang, L. P.; Liu, J. P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev., 2010, 42(2), 268-354.
77. Bookout, A. L.; Jeong, Y.; Downes, M.; Yu, R. T.; Evans, R. M.; Mangelsdorf, D. J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell, 2006, 126(4), 789-799.
78. Miki, Y.; Suzuki, T.; Tazawa, C; Blumberg, B.; Sasano, H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol, 2005, 231(1-2), 75-85.
79. Gascon-Barré, M.; Demers, C; Mirshahi, A.; Néron, S.; Zalzal, S.; Nanci, A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology., 2003, 37(5), 1034-1042.
80. Staudinger, J. L.; Goodwin, B.; Jones, S. A; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klaassen, CD.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(6), 3369-3374.
81. Zhang, J.; Huang, W.; Qatanani, M.; Evans, R. M.; Moore, D. D. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem., 2004, 279(47), 49517-49522.
82. Makishima, M.; Lu, T. T.; Xie, W.; Whitfield, G. K.; Domoto, H.; Evans, R. M.; Haussler, M. R.; Mangelsdorf, D. J. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002, 296(5571), 1313-1316.
83. Pascussi, J. M.; Drocourt, L.; Fabre, J. M.; Maurel, P.; Vilarem, M. J. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol. 2000, 58(2), 361-372.
84. Schuetz, E. G.; Schuetz, J. D.; Strom, S. C.; Thompson, M. T.; Fisher, R. A.; Molowa, D. T.; Li, D.; Guzelian, P. S. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology, 1993, 18(5), 1254-1262.
85. Schuetz, J. D.; Schuetz, E. G.; Thottassery, J. V.; Guzelian, P. S.; Strom, S.; Sun, D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol, 1996, 49(1), 63-72.
86. Honkakoski, P.; Zelko, I.; Sueyoshi, T.; Negishi, M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital- responsive enhancer module of the CYP2B gene. Mol. Cell. Biol., 1998, 18(10), 5652-5658.
87. Waxman, D. J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys., 1999, 369(1), 11-23.
88. Chen, Y.; Ferguson, S. S.; Negishi, M.; Goldstein, J. A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 308(2), 495-501.
89. Muller, F.; Fromm, M. F. Transporter-mediated drug-drug interactions. Pharmacogenomics, 2011, 12(7), 1017-1037.
90. Svoboda, M.; Riha, J.; Wlcek, K.; Jaeger, W.; Thalhammer, T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr. Drug Metab., 2011, 12(2), 139-153.
91. Meyer zu Schwabedissen, H. E.; Tirona, R. G.; Yip, C. S.; Ho, R. H.; Kim, R. B. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res., 2008, 68(22), 9338-9347.
92. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya, T.; Ishida, T.; Ohuchi, N.; Blumberg, B.; Sasano, H. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res., 2006, 66(1), 535-542.
93. Oscarson, M.; Zanger, U. M.; Rifki, O. F.; Klein, K.; Eichelbaum, M.; Meyer, U. A. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther., 2006, 80(5), 440-456.
94. Boyer, J. L.; Trauner, M.; Mennone, A.; Soroka, C. J.; Cai, S. Y.; Moustafa, T.; Zollner, G.; Lee, J. Y.; Ballatori, N., 2006, 290(6), G1124-G1130.
95. Landrier, J. F.; Eloranta, J. J.; Vavricka, S. R.; Kullak-Ublick, G. A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(3), G476-G485.
96. Jigorel, E.; Le Vee, M.; Boursier-Neyret, C; Parmentier, Y.; Fardel, O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drugsensing receptors in primary human hepatocytes. Drug Metab. Dispos., 2006, 34(10), 1756-1763.
97. Tachibana, S.; Yoshinari, K.; Chikada, T.; Toriyabe, T.; Nagata, K.; Yamazoe, Y. Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. Drug Metab. Dispos., 2009, 37(8), 1604-1610.
98. Saksena, S.; Goyal, S.; Raheja, G.; Singh, V.; Akhtar, M.; Nazir, T. M.; Alrefai, W. A.; Gill, RK.; Dudeja, P. K. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2011, 300(6), G1115-G1123.
99. Adibi, S. A. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 285(5), G779-G788.
100. Buckley, D. B.; Klaassen, CD. Induction of mouse UDP- glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor a, and nuclear factor erythroid 2-related factor 2. Drug Metab. Dispos., 2009, 37(4), 847-856.
101. Eeckhoudt, S. L.; Horsmans, Y.; Verbeeck, R. K. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica, 2002, 32(11), 975-984.
102. Owen, B. M.; Milona, A.; van Mil, S.; Clements, P.; Holder, J.; Boudjelal, M.; Cairns, W.; Parker, M.; White, R.; Williamson, C. Intestinal detoxification limits the activation of hepatic pregnane X receptor by lithocholic acid. Drug Metab. Dispos., 2010, 38(1), 143-149.
103. Mohamed, M. F.; Frye, R. F. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab. Dispos., 2010, 38(2), 270-275.
104. Rostami-Hodjegan, A.; Tucker, G. T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov., 2007, 6(2), 140-148.
105. Dickinson, G. L.; Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example. Br. J. Clin. Pharmacol., 2007, 64(1), 14-26.
106. Huang, L.; Berry, L.; Ganga, S.; Janosky, B.; Chen, A.; Roberts, J.; Colletti, A. E.; Lin, M. H. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab. Dispos., 2010, 38(2), 223-231.
107. Cubitt, H. E.; Yeo, K. R.; Howgate, E. M.; Rostami-Hodjegan, A.; Barter, Z. E. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica, 2011, 41(8), 623-638.
108. Shiran, M. R.; Proctor, N. J.; Howgate, E. M.; Rowland-Yeo, K.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 2006, 36(7), 567-580.
109. Yang, J.; Tucker, G. T.; Rostami-Hodjegan, A. Cytochrome P450 3A expression and activity in the human small intestine. Clin. Pharmacol. Ther., 2004, 76(4), 391.
110. Sjögren, E.; Lennernäs, H.; Andersson, T. B.; Gråsjö, J.; Bredberg, U. The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab. Dispos., 2009, 37(1), 47-58.
111. Donato, M. T.; Hallifax, D.; Picazo, L.; Castell, J. V.; Houston, J. B.; Gomez-Lechón, M. J.; Lahoz, A. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. Drug Metab. Dispos., 2010, 38(9), 1449-1455.
112. Kilford, P. J.; Stringer, R.; Sohal, B.; Houston, J. B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab. Dispos., 2009, 37(1), 82-89.
113. Bruyere, A.; Decleves, X.; Bouzom, F.; Proust, L.; Martinet, M.; Walther, B.; Parmentier, Y. Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica, 2009, 39(1), 22-32.
114. Kadono, K.; Akabane, T.; Tabata, K.; Gato, K.; Terashita, S.; Teramura, T. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab. Dispos., 2010, 38(7), 1230-1237.
115. Cubitt, H. E.; Houston, J. B.; Galetin, A. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab. Dispos. 2011, 39(5), 864-873.
116. Stringer, R. A.; Strain-Damerell, C.; Nicklin, P.; Houston, J. B. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab. Dispos., 2009, 37(5), 1025-1034.
117. Austin, R. P.; Barton, P.; Cockroft, S. L.; Wenlock, M. C.; Riley, R. J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos., 2002, 30(12), 1497-1503.
118. Kilford, P. J.; Gertz, M.; Houston, J. B.; Galetin, A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab. Dispos., 2008, 36(7), 1194-1197.
119. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther., 2009, 328(2), 652-662.
120. Zhang, Q.; Liu, Q.; Wu, J.; Wang, C.; Peng, J.; Ma, X.; Liu, K. PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. Eur. J. Pharmacol., 2009, 612(1-3), 9-14.
121. Dahan, A.; Amidon, G. L. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharm., 2009, 6(1), 19-28.
122. Guo, A.; Marinaro, W.; Hu, P.; Sinko, P. J. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos., 2002, 30(4), 457-463.
123. Kim, M. K.; Shim, C. K. The transport of organic cations in the small intestine: current knowledge and emerging concepts. Arch. Pharm. Res., 2006, 29(7), 605-616.
124. Gotoh, Y.; Kamada, N.; Momose, D. The advantages of the Ussing chamber in drug absorption studies. J. Biomol. Screen., 2005, 10(5), 517-523.
125. Tucker, T. G.; Milne, A. M.; Fournel-Gigleux, S.; Fenner, K. S.; Coughtrie, M. W. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem. Pharmacol, 2012, 83(2), 279-285.
126. Sun, H.; Pang, K. S. Physiological Modeling to Understand the Impact of Enzymes and Transporters on Drug and Metabolite Data and Bioavailability Estimates. Pharm. Res., 2010, 27(7), 1237-1254.
127. Yu, L. X.; Lipka, E.; Crison, J. R.; Amidon, G. L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev., 1996, 19(3), 359-376.
128. Yu, L. X.; Amidon, G. L. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 1998, 45(2), 199-203.
129. Suttle, A. B.; Pollack, G. M.; Brouwer, K. L. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentrationtime profiles. Pharm. Res., 1992, 9(3), 350-356.
130. Wright, J. D.; Ma, T.; Chu, C. K.; Boudinot, F. D. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-P- L-arabinofuranosyl) uracil (L-FMAU) in rats. Biopharm. Drug. Dispos., 1996, 17(3), 197-207.
131. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm., 1999, 186(2), 119-125.
132. Agoram, B.; Woltosz, W. S.; Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev., 2001, 50(Suppl 1), S41-S67.
133. Yu, L. X. An integrated model for determining causes of poor oral drug absorption. Pharm. Res., 1999, 16(12), 1883-1887.
134. Parrott, N.; Lave, T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm., 2008, 5(5), 760-775.
135. Gamsiz, E. D.; Ashtikar, M.; Crison, J.; Woltosz, W.; Bolger, M. B.; Carrier, R. L. Predicting the effect of fed-state intestinal contents on drug dissolution. Pharm. Res., 2010, 27(12), 2646-2656.
136. Hendriksen, B. A.; Felix, M. V.; Bolger, M. B. The composite solubility versus pH profile and its role in intestinal absorption prediction. AAPS PharmSci., 2003, 5(1), E4.
137. Parrott, N.; Lukacova, V.; Fraczkiewicz, G.; Bolger, M. B. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. AAPS J., 2009, 11(1), 45-53.
138. Tubic, M.; Wagner, D.; Spahn-Langguth, H.; Bolger, M. B.; Langguth, P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res., 2006, 23(8), 1712-1720.
139. Bolger, M. B.; Lukacova, V.; Woltosz, W. S. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J., 2009, 11(2), 353-363.
140. Abuasal, B. S.; Bolger, M. B.; Walker, D. K.; Kaddoumi, A. In silico modeling for the nonlinear absorption kinetics of UK-343, 664: a P-gp and CYP3A4 substrate. Mol. Pharm., 2012, 9(3), 492-504.
141. Sawamoto, T.; Haruta, S.; Kurosaki, Y.; Higaki, K.; Kimura, T. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J. Pharm. Pharmacol, 1997, 49(4), 450-457.
142. Kimura, T.; Higaki, K. Gastrointestinal transit and drug absorption. Biol. Pharm. Bull, 2002, 25(2), 149-164.
143. Yokoe, J.; Iwasaki, N.; Haruta, S.; Kadono, K.; Ogawara, K.; Higaki, K.; Kimura, T. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. J. Control. Release, 2003, 86(2-3), 305-313.
144. Kimura, T.; Iwasaki, N.; Yokoe, J. I.; Haruta, S.; Yokoo, Y.; Ogawara, K. I.; Higaki, K. Analysis and prediction of absorption profile including hepatic first-pass metabolism of N-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit- absorption model. Drug Metab. Dispos., 2000, 28(5), 577-581.
145. Willmann, S.; Schmitt, W.; Keldenich, J.; Dressman, J. B. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res., 2003, 20(11), 1766-1771.
146. Shono, Y.; Jantratid, E.; Janssen, N.; Kesisoglou, F.; Mao, Y.; Vertzoni, M.; Reppas, C; Dressman, J. B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm., 2009, 73(1), 107-114.
147. Pang, K. S.; Gillette, J. R. Sequential first-pass elimination of a metabolite derived from a precursor. J. Pharmacokinet. Biopharm., 1979, 7(3), 275-290.
148. Sun, H.; Pang, K. S. Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. Drug Metab. Dispos., 2009, 37(1), 187-202.
149. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci., 2005, 94(6), 1259-1276.
150. Rodgers, T.; Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci., 2006, 95(6), 1238-1257.
151. Rodgers, T.; Rowland, M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res., 2007, 24(5), 918-933.
152. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Nijsen, M. J.; Mackie, C. E.; Gilissen, R. A. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos., 2007, 35(10), 1766-1780.
153. Parrott, N.; Jones, H.; Paquereau, N.; Lavé, T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol, 2005, 96(3), 193-199.
154. Jones, H. M.; Parrott, N.; Jorga, K.; Lavé, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet, 2006, 45(5), 511-542.
155. Pang, K. S.; Chow, E. C. Prediction of flow effects on intestinal (FI) and systemic availability (Fsys) in PBPK intestine models: the traditional model (TM), segregated flow model (SFM) and QGut model. Drug Metab. Dispos., 2012, accepted.
156. Cong, D.; Doherty, M.; Pang, K. S. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab. Dispos., 2000, 28(2), 224-235.
157. Doherty, M. M.; Pang, K. S. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm. Res., 2000, 17(3), 291-298.
158. Lown, K. S.; Kolars, J. C.; Thummel, K. E.; Barnett, J. L.; Kunze, K. L.; Wrighton, S. A.; Watkins, P. B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos., 1994, 22(6), 947-955.
159. Lemahieu, W. P.; Maes, B. D.; Ghoos, Y.; Rutgeerts, P.; Verbeke, K.; Vanrenterghem, Y. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. Am. J. Physiol. Gastrointest. Liver Physiol, 2003, 285(3), G470-G482.
160. Lown, K. S.; Thummel, K. E.; Benedict, P. E.; Shen, D. D.; Turgeon, D. K.; Berent, S.; Watkins, P. B. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther., 1995, 57(1), 16-24.
161. Cong, D.; Fong, A. K.; Lee, R.; Pang, K. S. Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. Drug Metab. Dispos., 2001, 29(12), 1539-1547.
162. Liu, S.; Tam, D.; Chen, X.; Pang, K. S. P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: induction studies with pregnenolone-16α- carbonitrile. Drug Metab. Dispos., 2006, 34(9), 1468-1479.
163. Granger, D. N.; Richardson, P. D.; Kvietys, P. R.; Mortillaro, N. A. Intestinal blood flow. Gastroenterology, 1980, 78(4), 837-863.
164. Pang, K. S.; Durk, M. R. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J. Pharmacokinet. Biopharm., 2010, 37(6), 591-615.
165. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T., Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8(7), 676-684.
166. Yang, J.; Jamei, M.; Heydari, A.; Yeo, K. R.; de la Torre, R.; Farré, M.; Tucker, G. T.; Rostami-Hodjegan, A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol, 2006, 20(6), 842-849.
167. Valentin, J. in: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon, Oxford, 2002.
168. Gertz, M.; Harrison, A.; Houston, J. B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2012, 38(7), 1147-1158.
169. Petri, N.; Lennernäs, H. in: Drug Bioavailability - Estimation of Solubility, Permeability, Absorption and Bioavailability (van de Waterbeemd, H.; Lennernas, H. and Artursson, P. Eds.), Wiley-VCH, Weinheim, pp. 155-189, 2003.
170. Mitschke, D.; Reichel, A.; Fricker, G; Moenning, U. Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab. Dispos., 2008, 36(6), 1039-1045.
171. Fan, J.; Chen, S.; Chow, E. C.; Pang, K. S. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr. Drug Metab., 2010, 11(9), 743-761.
172. Paine, M. F.; Fisher, M. B. Immunochemical identification of UGT isoforms in human small bowel and in caco-2 cell monolayers. Biochem. Biophys. Res. Commun., 2000, 273(3), 1053-1057.
173. Teubner, W.; Meinl, W.; Florian, S.; Kretzschmar, M.; Glatt, H. Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem. J., 2007, 404(2), 207-215.
174. Mouly, S.; Paine, M. F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res., 2003, 20(10), 1595-1599.
175. Bruyère, A.; Declèves, X.; Bouzom, F.; Ball, K.; Marques, C; Treton, X.; Pocard, M.; Valleur, P.; Bouhnik, Y.; Panis, Y.; Scherrmann, J. M.; Mouly, S. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting Intestinal first pass. Mol. Pharm., 2010, 7(5), 1596-1607.
176. Meier, Y.; Eloranta, J. J.; Darimont, J.; Ismair, M. G.; Hiller, C; Fried, M.; Kullak-Ublick, G. A.; Vavricka, S. R. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos., 2007, 35(4), 590-594.
177. Lindahl, A.; Sjöberg, A.; Bredberg, U.; Toreson, H.; Ungell, A. L.; Lennernäs, H. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol. Pharm., 2004, 1(5), 347-356.
178. Chen, X.; Chen, F.; Liu, S.; Glaeser, H.; Dawson, P. A.; Hofmann, A. F.; Kim, R. B.; Shneider, B. L.; Pang, K. S. Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1α, 25-dihydroxyvitamin D3 via the vitamin D receptor. Mol. Pharmacol, 2006, 69(6), 1913-1923.
179. Dawson, P. A.; Hubbert, M.; Haywood, J.; Craddock, A. L.; Zerangue, N.; Christian, W. V.; Ballatori, N. The heteromeric organic solute transporter α-β, Ostα-Ostp, is an ileal basolateral bile acid transporter. J. Biol. Chem., 2005, 280(8), 6960-6968.
180. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab. Dispos., 2007, 35(6), 922-928.
181. Dahan, A.; Sabit, H.; Amidon, G. L. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab. Dispos., 2009, 37(10), 2028-2036.
182. Zhang, X.; Quinney, S. K.; Gorski, J. C.; Jones, D. R.; Hall, S. D. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab. Dispos., 2009, 37(8), 1587-1597.
183. Quinney, S. K.; Zhang, X.; Lucksiri, A.; Gorski, J. C.; Li, L.; Hall, S. D. Physiologically based pharmacokinetic model of mechanismbased inhibition of CYP3A by clarithromycin. Drug Metab. Dispos., 2010, 38(2), 241-248.
184. Quinney, S. K.; Galinsky, R. E.; Jiyamapa-Serna, V. A.; Chen, Y.; Hamman, M. A.; Hall, S. D.; Kimura, R. E. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab. Dispos., 2008, 36(6), 1097-1101.
185. Yan, G. Z.; Generaux, C. N.; Yoon, M.; Goldsmith, R. B.; Tidwell, R. R.; Hall, J. E.; Olson, C. A.; Clewell, H. J.; Brouwer, K. L.; Paine, M. F. A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab. Dispos., 2012, 40(1), 6-17.
186. Johnson, T. N.; Boussery, K.; Rowland-Yeo, K.; Tucker, G. T.; Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet., 2010, 49(3), 189-206.
187. Grillo, J. A.; Zhao, P.; Bullock, J.; Booth, B. P.; Lu, M.; Robie-Suh, K.; Berglund, E. G.; Pang, K. S.; Rahman, A.; Zhang, L.; Lesko, L. J.; Huang, S. M. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug. Dispos., 2012, 33(2), 99-110.
188. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009, 11(4), 740-746.
189. Wu, B. Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. J. Pharm. Sci., 2011, 101(3), 1281-1301.
190. Badhan, R.; Penny, J.; Galetin, A.; Houston, J. B. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J. Pharm. Sci., 2009, 98(6), 2180-2197.
191. Peters, S. A. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin. Pharmacokinet., 2008, 47(4), 245-259.
192. Pang, K. S.; Maeng, H. J.; Fan, J. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm., 2009, 6(6), 1734-1755.
193. Thörn, M.; Finnström, N.; Lundgren, S.; Rane, A.; Lööf, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol., 2005, 60(1), 54-60.
194. Lown, K. S.; Mayo, R. R.; Leichtman, A. B.; Hsiao, H. L.; Turgeon, D. K.; Schmiedlin-Ren, P.; Brown, M. B.; Guo, W.; Rossi, S. J.; Benet, L. Z.; Watkins, P. B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther., 1997, 62(3), 248-260.
195. Berggren, S.; Gall, C.; Wollnitz, N.; Ekelund, M.; Karlbom, U.; Hoogstraate, J.; Schrenk, D.; Lennernäs, H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm., 2007, 4(2), 252-257.
196. Dressman, J. B.; Thelen, K.; Willmann, S. An update on computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol., 2011, 7(11), 1345-1364.
197. Darwich, A. S.; Neuhoff, S.; Jamei, M.; Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM) " model. Curr. Drug Metab., 2010, 11(9), 716-729.
198. Wang, J.; Flanagan, D. R. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. J. Pharm. Sci., 1999, 88(7), 731-738.
199. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol., 2009, 5(2), 211-223.
200. Jamei, M.; Turner, D.; Yang, J.; Neuhoff, S.; Polak, S.; Rostami-Hodjegan, A.; Tucker, G. Population-based mechanistic prediction of oral drug absorption. AAPS J., 2009, 11(2), 225-237.
201. Zhu, C.; Jiang, L.; Chen, T. M.; Hwang, K. K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem., 2002, 37(5), 399-407.
202. Corti, G.; Maestrelli, F.; Cirri, M.; Furlanetto, S.; Mura, P. Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. Eur. J. Pharm. Sci., 2006, 27(4), 346-353.
203. Chiou, W. L.; Chung, S. M.; Wu, T. C.; Ma, C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther., 2001, 39(3), 93-101.
204. Lin, J. H. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc), 2004, 40(1), 5-22.
205. Cao, X.; Yu, L. X.; Barbaciru, C.; Landowski, C. P.; Shin, H. C.; Gibbs, S.; Miller, H. A.; Amidon, G. L.; Sun, D. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharm., 2005, 2(4), 329-340.
206. Chalasani, N.; Gorski, J. C.; Patel, N. H.; Hall, S. D.; Galinsky, R. E. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology, 2001, 34(6), 1103-1108.
207. Gertz, M.; Houston, J. B.; Galetin, A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos., 2011, 39(9), 1633-1642.
208. Won, C. S.; Oberlies, N. H.; Paine, M. F. Influence of dietary substances on intestinal drug metabolism and transport. Curr. Drug Metab., 2010, 11(9), 778-792.
209. Hajda, J.; Rentsch, K. M.; Gubler, C.; Steinert, H.; Stieger, B.; Fattinger, K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci., 2010, 41(5), 729-735.
210. Annaba, F.; Kumar, P.; Dudeja, A. K.; Saksena, S.; Gill, R. K.; Alrefai, W. A. Green tea catechin EGCG inhibits ileal apical sodium bile acid transporter ASBT. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298(3), G467-G473.
211. Lown, K. S.; Bailey, D. G.; Fontana, R. J.; Janardan, S. K.; Adair, C. H.; Fortlage, L. A.; Brown, M. B.; Guo, W.; Watkins, P. B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 1997, 99(10), 2545-2553.
212. Veronese, M. L.; Gillen, L. P.; Burke, J. P.; Dorval, E. P.; Hauck, W. W.; Pequignot, E.; Waldman, S. A.; Greenberg, H. E. Exposuredependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol., 2003, 43(8), 831-839.
213. Ngo, N.; Yan, Z.; Graf, T. N.; Carrizosa, D. R.; Kashuba, A. D.; Dees, E. C.; Oberlies, N. H.; Paine, M. F. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab. Dispos., 2009, 37(3), 514-522.
214. McConn, D. J., 2nd; Lin, Y. S.; Mathisen, T. L.; Blough, D. K.; Xu, Y.; Hashizume, T.; Taylor, S. L.; Thummel, K. E.; Shuhart, M. C. Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. Clin. Pharmacol. Ther., 2009, 85(4), 387-393.
215. Dreisbach, A. W.; Lertora, J. J. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metab. Toxicol., 2008, 4(8), 1065-1074.
216. Leblond, F. A.; Petrucci, M.; Dubé, P.; Bernier, G.; Bonnardeaux, A.; Pichette, V. Downregulation of intestinal cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol., 2002, 13(6), 1579-1585.
217. Dreisbach, A. W. The influence of chronic renal failure on drug metabolism and transport. Clin. Pharmacol. Ther., 2009, 86(5), 553-556.
218. Sun, H.; Frassetto, L. A.; Huang, Y.; Benet, L. Z. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin. Pharmacol. Ther., 2010, 87(4), 465-472.
219. Naud, J.; Michaud, J.; Boisvert, C.; Desbiens, K.; Leblond, F. A.; Mitchell, A.; Jones, C.; Bonnardeaux, A.; Pichette, V. Downregulation of intestinal drug transporters in chronic renal failure in rats. J. Pharmacol. Exp. Ther., 2007, 320(3), 978-985.
220. Veau, C.; Leroy, C.; Banide, H.; Auchère, D.; Tardivel, S.; Farinotti, R.; Lacour, B. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol. Dial. Transplant., 2001, 16(8), 1607-1614.
221. Pichette, V.; Leblond, F. A. Drug metabolism in chronic renal failure. Curr. Drug Metab., 2003, 4(2), 91-103.
222. Hirata, S.; Izumi, S.; Furukubo, T.; Ota, M.; Fujita, M.; Yamakawa, T.; Hasegawa, I.; Ohtani, H.; Sawada, Y. Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int. J. Clin. Pharmacol. Ther., 2005, 43(1), 30-36.
223. Buchman, A. L.; Paine, M. F.; Wallin, A.; Ludington, S. S. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci., 2005, 50(12), 2312-2315.
224. Wojtal, K. A.; Eloranta, J. J.; Hruz, P.; Gutmann, H.; Drewe, J.; Staumann, A.; Beglinger, C; Fried, M.; Kullak-Ublick, G. A.; Vavricka, S. R. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab. Dispos., 2009, 37(9), 1871-1877.
225. Bukhari, F. J.; Moradi, H.; Gollapudi, P.; Ju Kim, H.; Vaziri, N. D.; Said, H. M. Effect of chronic kidney disease on the expression of thiamin and folic acid transporters. Nephrol. Dial. Transplant. 2011, 26(7), 2137-2144.
226. Shimizu, Y.; Masuda, S.; Nishihara, K.; Ji, L.; Okuda, M.; Inui, K. Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. Am. J. Physiol. Gastrointest. Liver Physiol, 2005, 288(4), G664-G670.
227. Rowland Yeo, K.; Jamei, M.; Yang, J.; Tucker, G. T.; Rostami-Hodjegan, A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 2010, 39(5), 298-309.
228. Tachibana, T.; Kato, M.; Takano, J.; Sugiyama, Y. Predicting drugdrug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr. Drug Metab., 2010, 11(9), 762-777.
229. Franke, R. M.; Lancaster, C. S.; Peer, C. J.; Gibson, A. A.; Kosloske, A. M.; Orwick, S. J.; Mathijssen, R. H.; Figg, W. D.; Baker, S. D.; Sparreboom, A. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin. Pharmacol. Ther., 2011, 89(5), 693-701.
230. Guest, E. J.; Rowland-Yeo, K.; Rostami-Hodjegan, A.; Tucker, G. T.; Houston, J. B.; Galetin, A. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br. J. Clin. Pharmacol, 2011, 71(1), 72-87.
231. Zhao, P.; Vieira Mde, L.; Grillo, J. A.; Song, P.; Wu, T. C.; Zheng, J. H.; Arya, V.; Berglund, E. G.; Atkinson, A. J., Jr.; Sugiyama, Y.; Pang, K. S.; Reynolds, K. S.; Abernethy, D. R.; Zhang, L.; Lesko, L. J.; Huang, S. M. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol, 2012, 52(1 Suppl), 91S-108S.
232. Rowland Yeo, K.; Aarabi, M.; Jamei, M.; Rostami-Hodjegan, A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev. Clin. Pharmacol, 2011, 4(2), 261-274.
233. Ghobadi, C; Johnson, T. N.; Aarabi, M.; Almond, L. M.; Allabi, A. C.; Rowland-Yeo, K.; Jamei, M.; Rostami-Hodjegan, A. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin. Pharmacokinet., 2011, 50(12), 809-822.
234. Johnson, T. N.; Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth., 2011, 21(3), 291-301.
235. Sun, H.; Zeng, Y. Y.; Pang, K. S. Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17β-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR-and Wistar rat liver preparations. Drug Metab. Dispos., 2010, 38(5), 769-780.
236. Endres, C. J.; Endres, M. G.; Unadkat, J. D. Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol. Pharm., 2009, 6(6), 1756-1765.
237. Darwich, A. S.; Henderson, K.; Burgin, A.; Ward, N.; Whittam, J.; Ammori, B. J.; Ashcroft, D. M.; Rostami-Hodjegan, A. Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes. Br. J. Clin. Pharmacol, 2012. doi: 10.1111/j.1365-2125.2012.04284.x.
238. Rostami-Hodjegan, A.; Tamai, I.; Pang, K. S. Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay! Biopharm. Drug. Dispos., 2012, 33(2), 47-50.
239. Rowland, M.; Peck, C.; Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol., 2011, 51, 45-73.
240. Huang, S. M. Invited commentary: PBPK as a tool in regulatory review. Biopharm. Drug. Dispos., 2012, 33, 51-52.
241. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci., 2002, 91(5), 1358-1370.
242. Huang, S. M.; Rowland, M. (2012) The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther., 2012, 91(3), 542-549.
243. Galetin, A.; Hinton, L. K.; Burt, H.; Obach, R. S.; Houston, J. B. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug Metab., 2007, 8(7), 685-693.
244. Gomez, D. Y.; Wacher, V. J.; Tomlanovich, S. J.; Hebert, M. F.; Benet, L. Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther., 1995, 58(1), 15-19.
245. Yokomasu, A.; Yano, I.; Sato, E.; Masuda, S.; Katsura, T.; Inui, K. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. Biopharm. Drug. Dispos., 2009, 30(9), 517-523.
246. Mizuma, T.; Kawashima, K.; Sakai, S.; Sakaguchi, S.; Hayashi, M. Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans. J. Pharm. Sci., 2005, 94(3), 571-575.
247. Kato, M.; Chiba, K.; Hisaka, A.; Ishigami, M.; Kayama, M.; Mizuno, N.; Nagata, Y.; Takakuwa, S.; Tsukamoto, Y.; Ueda, K.; Kusuhara, H.; Ito, K.; Sugiyama, Y. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet., 2003, 18(6), 365-372.
248. Ogasawara, A.; Utoh, M.; Nii, K.; Ueda, A.; Yoshikawa, T.; Kume, T.; Fukuzaki, K. Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab. Dispos., 2009, 37(1), 122-128.
249. Qin, X. L.; Bi, H. C.; Wang, X. D.; Li, J. L.; Wang, Y.; Xue, X. P.; Chen, X.; Wang, C. X.; Xu le, J.; Wang, Y. T.; Huang, M. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int. J. Pharm., 2010, 389(1-2), 114-121.
250. Sandström, R.; Knutson, T. W.; Knutson, L.; Jansson, B.; Lennernäs, H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol, 1999, 48(2), 180-189.
251. Yokomasu, A.; Yano, I.; Sato, E.; Masuda, S.; Katsura, T.; Inui, K. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. Drug Metab. Pharmacokinet, 2008, 23(6), 469-475.
252. Kupferschmidt, H. H.; Fattinger, K. E.; Ha, H. R.; Follath, F.; Krähenbühl, S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol, 1998, 45(4), 355-359.
253. Choi, D. H.; Chang, K. S.; Hong, S. P.; Choi, J. S.; Han, H. K. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. Biopharm. Drug. Dispos., 2008, 29(1), 45-50.
254. Lam, Y. W.; Ereshefsky, L.; Port, A.; Timmer, C. J.; Dogterom, P. Effects of Rifampin on the Disposition of Gepirone ER and its Metabolites. The Open Drug Metab. J., 2009, 3(1), 1-7.
255. Hebert, M. F.; Roberts, J. P.; Prueksaritanont, T.; Benet, L. Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther., 1992, 52(5), 453-457.
256. Holtbecker, N.; Fromm, M. F.; Kroemer, H. K.; Ohnhaus, E. E.; Heidemann, H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab. Dispos., 1996, 24(10), 1121-1123.
257. Chow, E. C.; Maeng, H. J.; Liu, S.; Khan, A. A.; Groothuis, G. M. Pang,; K. S. 1α, 25-Dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug. Dispos., 2009, 30(8), 457-475.
258. Huijghebaert, S. M.; Sim, S. M.; Back, D. J.; Eyssen, H. J. Distribution of estrone sulfatase activity in the intestine of germfree and conventional rats. J. Steroid Biochem., 1984, 20(5), 1175-1179.
259. Pinkus, L. M.; Ketley, J. N.; Jakoby, W. B. The glutathione S-transferases as a possible detoxification system of rat intestinal epithelium. Biochem. Pharmacol, 1977, 26(24), 2359-2363.
260. Englund, G.; Rorsman, F.; Rönnblom, A.; Karlbom, U.; Lazorova, L.; Gråsjö, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29(3-4), 269-277.
261. Ballatori, N.; Christian, W. V.; Lee, J. Y.; Dawson, P. A.; Soroka, C. J.; Boyer, J. L.; Madejczyk, M. S.; Li, N. OSTα-OSTP: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology, 2005, 42(6), 1270-1279.
262. Rao, A.; Haywood, J.; Craddock, A. L.; Belinsky, M. G.; Kruh, G. D.; Dawson, P. A. The organic solute transporter α-P, Ostα-Ostp, is essential for intestinal bile acid transport and homeostasis. Proc. Natl. Acad. Sci. USA, 2008, 105(10), 3891-3896.